{"id":61717,"date":"2025-08-12T16:05:26","date_gmt":"2025-08-12T14:05:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/catalyst-orthoscience-announces-full-commercial-release-of-fracture-shoulder-system\/"},"modified":"2025-08-12T16:05:26","modified_gmt":"2025-08-12T14:05:26","slug":"catalyst-orthoscience-announces-full-commercial-release-of-fracture-shoulder-system","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/catalyst-orthoscience-announces-full-commercial-release-of-fracture-shoulder-system\/","title":{"rendered":"Catalyst OrthoScience Announces Full Commercial Release of Fracture Shoulder System"},"content":{"rendered":"
\n

\nThe new system, designed to improve reverse shoulder arthroplasty for proximal humeral fractures, includes patented technology that helps reduce surgical complexity and drive clinical confidence<\/i><\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

NAPLES, Fla.–(BUSINESS WIRE)–Catalyst OrthoScience Inc.<\/a> (\u201cCatalyst\u201d), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announced today the full commercial release of the Catalyst Fracture Shoulder System. While this marks the latest innovation in Catalyst\u2019s expanding portfolio, the company continues to expand its momentum within the orthopedic community \u2013 underscored by recently published midterm data from its Catalyst CSR\u2122, which demonstrates industry-leading Single-Assessment Numeric Evaluation (SANE) scores.<\/p>\n

\n\u201cAt Catalyst, we\u2019re not bound by convention \u2013 we\u2019re defining what comes next,\u201d said Carl O\u2019Connell, president and chief executive officer of Catalyst. \u201cOur technology is designed to solve real shoulder arthroplasty challenges, and our clinical outcomes prove the value of that approach. We\u2019re committed to helping shoulder surgeons achieve better results with less complexity.\u201d<\/p>\n

\nThis release continues to expand Catalyst\u2019s differentiated portfolio, bringing a fracture-specific solution that prioritizes tuberosity fixation and healing\u2014key factors consistently shown to produce better outcomes. Designed to improve reverse shoulder arthroplasty for proximal humeral fractures (PHFs), the system includes patented technology that helps reduce surgical complexity and drive clinical confidence. Entering a fracture market estimated at over $250 million, Catalyst is seeing strong early adoption and is positioned to capture significant market share.<\/p>\n

\nThe news comes on the heels of its recent announcement of 5-8 year published midterm data supporting its Catalyst CSR\u2122 Total Shoulder System – the first product Catalyst launched to the market. Catalyst continues to provide solutions that enable surgeons to deliver outcomes that outpace traditional total shoulder arthroplasty (TSA) solutions and this independent study introduced a new industry benchmark, showing that:<\/p>\n